Synthesising registry data (psoriatic arthritis)
In recent years, an increasing number of biologic therapies have been made available for the treatment of psoriatic arthritis (PsA). Biologics are particularly effective at controlling the symptoms of PsA and have been shown to delay disease progression in terms of joint erosion. However, these treatments are expensive, and within resource constrained systems, their value for money has been assessed by health technology assessment (HTA) agencies to determine whether they should be approved for reimbursement in public health care systems. 

Many HTA agencies require robust evidence demonstrating that a drug therapy is cost-effective, as well as clinically effective, to receive a positive reimbursement decision. As a result, cost-effectiveness evidence has come to play a prominent role in decisions regarding the approval of biologic treatments in many settings. Unfortunately, the development of robust cost-effectiveness evidence for PsA treatments has often been hindered by deficiencies in the evidence base. The short-term nature of many phase 3 trials in this area means that assumptions regarding the long-term efficacy of biologics are required to investigate the cost-effectiveness of biologic therapies over the remaining lifetime of an average patient. Consequently, this can impose additional uncertainty surrounding the results and, ultimately, reduce confidence in a decision to accept or reject a treatment for reimbursement. 

We aimed to explore the extent to which existing registry data can be used to inform cost-effectiveness analysis studies involving biologic therapies for the treatment of PsA. The second aim was to identify how data collection in PsA registries might be improved to inform future cost-effectiveness analysis research. 

Read about our research in more detail by accessing our publication on How to appropriately extrapolate costs and utilities in cost-effectiveness analysis?